Interview with Peter Martin, COO, Norgine
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor…
Address: Norgine
Norgine House
Widewater Place
Moorhall Road
Harefield
Uxbridge
UB9 6NS UK
Tel: +44 (0) 1895 826 600
Norgine is a specialty pharmaceutical company with an extensive and balanced pan-European presence. Above and beyond Europe, its products are sold in a total of 53 countries worldwide. Its areas of expertise are principally in gastroenterology, hepatology and incontinence.
Founded in 1906 by Dr Victor Stein, Norgine is still privately owned and Peter Stein, a grand-nephew of the founder, is now Chairman and CEO. The company’s core focus is on gastroenterology and hepatology. Norgine develops and manufactures innovative pharmaceutical products, which are then marketed through their own subsidiaries and in collaboration with a network of partners around the world.
Norgine’s total revenue in 2009 was €257 million. In 2009 product sales increased to €253 million, the 23rd consecutive year of double-digit growth at constant exchange rates. MOVICOL is Norgine’s number one product and accounts for over 50% of total sales.
Norgine currently has a strong product development pipeline including a number of projects entering advanced clinical studies.
The company has a manufacturing facility in the UK, but no R&D.
Movicol
Moviprep
Klean-Prep
Oramorph
Normacol
Pyralvex
Spasmonal
Fivasa
Nortussine
Xifaxan
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor…
Belén Garijo, global CEO of Merck Healthcare, speaking this month at the FT Global Pharmaceutical and Biotechnology Conference, ‘Thriving Amid Uncertainty’, in London, underlined the significance of Merck’s new deal…
Hamid Yunis, partner and head of healthcare at the London office of international law firm, McDermott Will & Emery, discusses the potential negative impact of Brexit and the UK leaving…
Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing…
In an exclusive interview at the eyeforpharma Barcelona Summit 2016, Janssen EMEA’s Jane Griffiths speaks out about patient-centricity, sustainability and the dawning of a new world of healthcare. What’s been keeping you…
In an exclusive interview at the eyeforpharma Barcelona Summit 2016, GSK’s Danie Du Plessis speaks out about patient-centricity and the growing role of medical affairs in the pharma industry. In your…
Can you provide us with an overview of what the UK market represents for the greater Lonza group? Lonza Biologics is a contract manufacturing organisation employing approximately 650 people in…
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared to the US or emerging markets? Gary…
Following the acquisition of Arrow Generics by Watson in December 2009, what complementarities and synergies were generated from the transaction and where do you stand today with the integration? Since…
As a partner at Apposite since the company was created in 2006, what was the founding vision of the company and what do you consider have been its major milestones…
Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is the history behind this…
As the global economic roller coaster continues to unfold, governments the world over have desperately been scrambling to find the right policies that will effectively clamp on the brakes to…
See our Cookie Privacy Policy Here
